These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9395198)

  • 1. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.
    Peters JM; Cattley RC; Gonzalez FJ
    Carcinogenesis; 1997 Nov; 18(11):2029-33. PubMed ID: 9395198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats.
    Marsman DS; Cattley RC; Conway JG; Popp JA
    Cancer Res; 1988 Dec; 48(23):6739-44. PubMed ID: 3180084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures.
    Karam WG; Ghanayem BI
    Carcinogenesis; 1997 Nov; 18(11):2077-83. PubMed ID: 9395205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643.
    Rose ML; Germolec D; Arteel GE; Schoonhoven R; Thurman RG
    Chem Res Toxicol; 1997 Oct; 10(10):1198-204. PubMed ID: 9348444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster.
    Lake BG; Evans JG; Cunninghame ME; Price RJ
    Environ Health Perspect; 1993 Dec; 101 Suppl 5(Suppl 5):241-7. PubMed ID: 8013414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver.
    Cattley RC; Marsman DS; Popp JA
    Carcinogenesis; 1991 Mar; 12(3):469-73. PubMed ID: 1849052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased nuclear ploidy, not cell proliferation, is sustained in the peroxisome proliferator-treated rat liver.
    Lalwani ND; Dethloff LA; Haskins JR; Robertson DG; de la Iglesia FA
    Toxicol Pathol; 1997; 25(2):165-76. PubMed ID: 9125775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor alpha.
    Pogribny IP; Tryndyak VP; Woods CG; Witt SE; Rusyn I
    Mutat Res; 2007 Dec; 625(1-2):62-71. PubMed ID: 17586532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of the hepatocarcinogenesis caused by dehydroepiandrosterone, a peroxisome proliferator, in male F-344 rats.
    Hayashi F; Tamura H; Yamada J; Kasai H; Suga T
    Carcinogenesis; 1994 Oct; 15(10):2215-9. PubMed ID: 7955056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation.
    Kiss A; Ortiz-Aguayo R; Sharp R; Merlino G; Thorgeirsson SS; Gonzalez FJ; Peters JM
    Carcinogenesis; 2001 Jun; 22(6):975-9. PubMed ID: 11375907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on the expression of c-met, c-myc and PPAR-alpha in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643.
    Miller RT; Glover SE; Stewart WS; Corton JC; Popp JA; Cattley RC
    Carcinogenesis; 1996 Jun; 17(6):1337-41. PubMed ID: 8681452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR: a mediator of peroxisome proliferator action.
    Green S
    Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic expression of acute-phase protein genes during carcinogenesis induced by peroxisome proliferators.
    Anderson SP; Cattley RC; Corton JC
    Mol Carcinog; 1999 Dec; 26(4):226-38. PubMed ID: 10569800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-induced adenomas.
    Miller RT; Anderson SP; Corton JC; Cattley RC
    Carcinogenesis; 2000 Apr; 21(4):647-52. PubMed ID: 10753199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14,643.
    Glauert HP; Eyigor A; Tharappel JC; Cooper S; Lee EY; Spear BT
    Toxicol Sci; 2006 Apr; 90(2):331-6. PubMed ID: 16434500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver.
    Cattley RC; Popp JA
    Cancer Res; 1989 Jun; 49(12):3246-51. PubMed ID: 2566380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643.
    Marsman DS; Popp JA
    Carcinogenesis; 1994 Jan; 15(1):111-7. PubMed ID: 7507413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid.
    Marsman DS; Goldsworthy TL; Popp JA
    Carcinogenesis; 1992 Jun; 13(6):1011-7. PubMed ID: 1600604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.
    Peters JM; Rusyn I; Rose ML; Gonzalez FJ; Thurman RG
    Carcinogenesis; 2000 Apr; 21(4):823-6. PubMed ID: 10753222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883.
    Eacho PI; Lanier TL; Brodhecker CA
    Carcinogenesis; 1991 Sep; 12(9):1557-61. PubMed ID: 1893515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.